Effects of Vitamin D₃ Supplementation on Cardiovascular and Cancer Outcomes by eGFR in VITAL.

ABSTRACT:

Background

Reduced 25-hydroxyvitamin D (25[OH]D) metabolism and secondary hyperparathyroidism are common with lower estimated glomerular filtration rate (eGFR) and may contribute to cardiovascular disease and cancer risk.

Methods

We assessed for heterogeneity by baseline eGFR of the effects of vitamin D₃ on cardiovascular and cancer outcomes in the Vitamin D and Omega-3 Trial (VITAL). Participants were randomized to 2000 IU vitamin D₃ and/or 1 g Ω-3 fatty acids daily using a placebo-controlled, two-by-two factorial design (5.3 years follow-up). Primary study end points were incident major cardiovascular events and invasive cancer. Changes in serum 25(OH)D and parathyroid hormone (PTH) were examined.

Results

Baseline eGFR was available for

SUBMITTER: Limonte CP 

PROVIDER: S-EPMC9802543 | biostudies-literature | 2022 Dec

REPOSITORIES: biostudies-literature